Telomir Pharma touts breakthrough in drug-resistant infections

Telomir Pharmaceuticals (Nasdaq: TLO), a US age-reversal science-based biotech, has identified Telomir-Ag2 as a novel drug candidate for the treatment of bacterial infections, including those caused by drug-resistant pathogens.

This follows Telomir’s recent breakthrough in stabilizing Silver(II) in a biologically compatible form using its proprietary Telomir-1 platform, said Telomir, whose shares edged up 3% to $2.75 on the news.

Telomir-Ag2 is a stabilized Silver(II) complex that demonstrated broad-spectrum antimicrobial activity in pre-clinical studies, including against methicillin- and aminoglycoside-resistant Staphylococcus aureus (MARSA), one of the most challenging pathogens in clinical settings.